Rapidly growing tissue regeneration company
LifeCell was headquartered in New Jersey and traded on the NASDAQ under symbol LIFC. The Company develops tissue-based products for use in reconstructive, orthopedic and urogynecologic surgical procedures to repair soft tissue defects. LifeCell’s technology produces a regenerative tissue matrix that creates a biological framework for organizing the same tissue regeneration process that the body undergoes to repair worn or damaged tissue. Leading products include AlloDerm and Strattice. Kinetic Concepts, Inc. (KCI) acquired LifeCell for $1.7 Billion in cash in 2008.
- In 2003, Essex Woodlands acquired a stake in the publicly traded shares of LifeCell.
- Following the initial growth equity investment, Essex Woodlands worked with LifeCell’s management team to expand market penetration of the core product (AlloDerm) and successfully launch new pipeline products.
- At the time of EW’s exit, LifeCell was generating over $190M in Sales.